drugset / Trial / NCT00654680

Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury

NCT00654680

Phase 3 Completed 418 enrolled Bayer GlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Investigate efficacy and safety of Vardenafil in patients with spinal cord injury

Timeline

Start
2002-10
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 5 mg
Subject Vardenafil Small molecule 10 mg
Subject Vardenafil Small molecule 20 mg

Indications